ABUS - Arbutus to Present Imdusiran Data at EASL Congress 2024 | Benzinga
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy.
The accepted abstracts for presentation are as follows:
Abstract Number: 2389
Presentation Type: Poster presentation
Title: Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment.
Presenter: Prof. Man-Fung Yuen
Presentation Date: June 5, 2024
Key Findings: HBsAg ? LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN, but in 0 subjects who received 4 or 5 doses of imdusiran plus 12 weeks of IFN. The study remains ongoing and additional end-of-treatment data, durability of end-of-treatment HBsAg loss, and preliminary immunology data for a subset of study subjects will be presented.
This poster will also be featured in the Poster Tour: Viral hepatitis B and D: New therapies, unapproved therapies or strategies, on Thursday, June 6.
Abstract Number: 505
Presentation Type: Oral presentation
Title: Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone.
Presenter: Prof. Kosh Agarwal
Presentation Date: June 6, 2024
Key Findings: Repeat dosing of imdusiran for 24 weeks followed by VTP-300 was well-tolerated and contributes to the maintenance of lower HBsAg levels compared to placebo in subjects who have reached end-of-treatment and follow up week 60. More subjects who received VTP-300 have qualified to stop NA-therapy at end-of-treatment and all remain off therapy. Additional on-treatment, follow-up and NA discontinuation data will be presented.
Abstracts are available on the ...